GeoVax Labs is a clinical-stage biotechnology company developing immunotherapies and vaccines against infectious diseases and solid tumor cancers using vector vaccine platforms. Co.'s product pipeline includes human clinical trials in COVID-19 vaccine and a theraphy against head and neck cancer. Additional research and development programs include preventive vaccines against Monkeypox, hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa) and Zika virus, as well as immunotherapies for multiple solid tumors. Co.'s cancer therapy programs are Gedeptin® and MUC1-based Immunotherapy. The GOVX stock yearly return is shown above.
The yearly return on the GOVX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the GOVX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|